Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MDR-TB

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

Study shows Otsuka’s TB drug works even in worst cases

Deltybaeffective even in cases that are unlikely to respond to any other drug

- PMLiVE

Lundbeck and Otsuka’s Rexulti set for August launch in US

Follows the antipsychotic drug's FDA approval on Friday

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

Otsuka expands CNS presence with Avanir purchase

Deal for US biotech is valued at $3.5bn

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

- PMLiVE

Otsuka and Lundbeck file Abilify follow-up in the US

Brexpiprazole to be reviewed for use in schizophrenia and major depressive disorder

- PMLiVE

Otsuka launches European ADPKD forum

Aims to lead awareness raising plans for rare genetic condition

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

EU flag

Europe extends clinical trial project with African researchers

Partnership has already developed eight improved medical treatments

- PMLiVE

Otsuka wins approval for TB drug Deltyba

Second drug approved by EC in 2014 for multidrug resistant tuberculosis

- PMLiVE

Tuberculosis: treatment and prevention

One of the most significant global diseases, effective new TB therapies are sorely needed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links